CLLS Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.950

Open

3.840

VWAP

3.83

Vol

41.53K

Mkt Cap

384.26M

Low

3.720

Amount

159.05K

EV/EBITDA(TTM)

--

Total Shares

100.59M

EV

226.60M

EV/OCF(TTM)

--

P/S(TTM)

5.99

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Show More

Events Timeline

(ET)

2025-12-15

17:50:00

Allogene Therapeutics Wins Arbitration Against Cellectis

2025-12-15

17:00:00

Cellectis Announces Arbitration Decision Against Servier

2025-11-07 (ET)

2025-11-07

16:32:54

Cellectis announces Q3 adjusted EPS of 2 cents compared to a loss of 22 cents in the previous year.

2025-11-03 (ET)

2025-11-03

09:24:50

Cellectis to share progress on eti-cel at ASH 2025

2025-03-13 (ET)

2025-03-13

18:11:13

Cellectis reports Q4 EPS (64c) vs (17c) last year

2025-01-15 (ET)

2025-01-15

15:38:10

Cellectis files to sell 44M ordinary shares for holders

News

Globenewswire

01-08Globenewswire

Cellectis Initiates Pivotal Trials for Lasme-cel and Eti-cel, 2026 Outlook Positive

Newsfilter

01-06Newsfilter

Autolus Evaluates Cellares' Automated Platform for Manufacturing Expansion

Benzinga

2025-12-23Benzinga

Cellectis SA Receives Buy Rating with $9 Price Target from Clear Street

Benzinga

2025-12-16Benzinga

Cellectis Shares Under Pressure Following Allogene Arbitration Win on Tuesday

Benzinga

2025-12-16Benzinga

Lightwave Logic, Kyverna Therapeutics, and Other Major Stocks Decline in Tuesday's Pre-Market Trading

Globenewswire

2025-12-15Globenewswire

Allogene Secures Global Control of Cema-Cel, Interim Analysis Set for 1H 2026

4 Analyst Rating

Wall Street analysts forecast CLLS stock price to rise

2 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

4.00

Averages

7.00

High

9.00

Current: 0.000

Low

4.00

Averages

7.00

High

9.00

Clear Street

Bill Maughan

initiated

$9

AI Analysis

2025-12-22

Reason

Clear Street

Bill Maughan

Price Target

$9

AI Analysis

2025-12-22

initiated

Reason

Clear Street analyst Bill Maughan initiated coverage of Cellectis with a Buy rating and $9 price target. Cellectis has produced "strong" efficacy data from its initial program, lasme-cel in acute lymphoblastic leukemia, and "an encouraging initial efficacy signal" from eti-cel in non-hodgkin's lymphoma, which the firm believes positions Cellectis well to be among the first companies to bring an allogenic CAR-T product for the treatment of hematological cancers to market.

Wells Fargo

Nick Abbott

Equal Weight

maintain

$3 -> $4

2025-10-20

Reason

Wells Fargo

Nick Abbott

Price Target

$3 -> $4

2025-10-20

maintain

Equal Weight

Reason

Wells Fargo analyst Nick Abbott raised the firm's price target on Cellectis to $4 from $3 and keeps an Equal Weight rating on the shares. The firm says new data from DL3 of ALL study are promising, with high CR/CRi & MRD-ve rates in patients with few options. Clarity on regulatory path is also positive, Wells adds. Pivotal Phase 2 execution is now key, with first data Q4 2026 and BLA filing in the second half of 2028, along with clarity on market size/opportunity.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CLLS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Cellectis SA (CLLS.O) is -4.69, compared to its 5-year average forward P/E of -1.73. For a more detailed relative valuation and DCF analysis to assess Cellectis SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.73

Current PE

-4.69

Overvalued PE

0.24

Undervalued PE

-3.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.55

Current EV/EBITDA

-4.43

Overvalued EV/EBITDA

-0.76

Undervalued EV/EBITDA

-4.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

4.94

Current PS

4.81

Overvalued PS

7.40

Undervalued PS

2.48

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

high growth stocks trading under $5

Intellectia · 184 candidates

Price: <= $5.00Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

TDH Holdings Inc

10.74M

ReTo Eco-Solutions Inc

2.60M

Iovance Biotherapeutics Inc

1000.00M

Loop Industries Inc

61.87M

Evaxion A/S

26.61M

Onconetix Inc

1.65M

Whales Holding CLLS

Long Focus Capital Management LLC

Bpifrance Participations SA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Cellectis SA (CLLS) stock price today?

The current price of CLLS is 3.82 USD — it has increased 6.11

What is Cellectis SA (CLLS)'s business?

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

What is the price predicton of CLLS Stock?

Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is7.00 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cellectis SA (CLLS)'s revenue for the last quarter?

Cellectis SA revenue for the last quarter amounts to NaN USD, decreased

What is Cellectis SA (CLLS)'s earnings per share (EPS) for the last quarter?

Cellectis SA. EPS for the last quarter amounts to USD, decreased

How many employees does Cellectis SA (CLLS). have?

Cellectis SA (CLLS) has 224 emplpoyees as of March 11 2026.

What is Cellectis SA (CLLS) market cap?

Today CLLS has the market capitalization of 384.26M USD.